Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Interest Expense - Others (2016 - 2022)

Historic Interest Expense - Others for BioRestorative Therapies (BRTX) over the last 8 years, with Q2 2022 value amounting to $46613.0.

  • BioRestorative Therapies' Interest Expense - Others fell 9081.21% to $46613.0 in Q2 2022 from the same period last year, while for Jun 2022 it was $1.3 million, marking a year-over-year increase of 3171.23%. This contributed to the annual value of $1.8 million for FY2021, which is 40142.55% up from last year.
  • According to the latest figures from Q2 2022, BioRestorative Therapies' Interest Expense - Others is $46613.0, which was down 9081.21% from $29011.0 recorded in Q1 2022.
  • Over the past 5 years, BioRestorative Therapies' Interest Expense - Others peaked at $507332.0 during Q2 2021, and registered a low of $24168.0 during Q2 2020.
  • For the 5-year period, BioRestorative Therapies' Interest Expense - Others averaged around $236831.3, with its median value being $230383.0 (2018).
  • Its Interest Expense - Others has fluctuated over the past 5 years, first crashed by 9263.1% in 2020, then soared by 199918.9% in 2021.
  • BioRestorative Therapies' Interest Expense - Others (Quarter) stood at $283247.0 in 2018, then soared by 39.39% to $394816.0 in 2019, then tumbled by 42.33% to $227683.0 in 2020, then fell by 6.09% to $213815.0 in 2021, then tumbled by 78.2% to $46613.0 in 2022.
  • Its Interest Expense - Others was $46613.0 in Q2 2022, compared to $29011.0 in Q1 2022 and $213815.0 in Q4 2021.